308 related articles for article (PubMed ID: 28032312)
1. Molecular Approaches in HFpEF: MicroRNAs and iPSC-Derived Cardiomyocytes.
Kriegel AJ; Gartz M; Afzal MZ; de Lange WJ; Ralphe JC; Strande JL
J Cardiovasc Transl Res; 2017 Jun; 10(3):295-304. PubMed ID: 28032312
[TBL] [Abstract][Full Text] [Related]
2. Combining patient proteomics and in vitro cardiomyocyte phenotype testing to identify potential mediators of heart failure with preserved ejection fraction.
Raphael R; Purushotham D; Gastonguay C; Chesnik MA; Kwok WM; Wu HE; Shah SJ; Mirza SP; Strande JL
J Transl Med; 2016 Jan; 14():18. PubMed ID: 26792056
[TBL] [Abstract][Full Text] [Related]
3. microRNA-21 promotes cardiac fibrosis and development of heart failure with preserved left ventricular ejection fraction by up-regulating Bcl-2.
Dong S; Ma W; Hao B; Hu F; Yan L; Yan X; Wang Y; Chen Z; Wang Z
Int J Clin Exp Pathol; 2014; 7(2):565-74. PubMed ID: 24551276
[TBL] [Abstract][Full Text] [Related]
4. Gender and cardiovascular disease: are sex-biased microRNA networks a driving force behind heart failure with preserved ejection fraction in women?
Florijn BW; Bijkerk R; van der Veer EP; van Zonneveld AJ
Cardiovasc Res; 2018 Feb; 114(2):210-225. PubMed ID: 29186452
[TBL] [Abstract][Full Text] [Related]
5. Pathophysiological understanding of HFpEF: microRNAs as part of the puzzle.
Rech M; Barandiarán Aizpurua A; van Empel V; van Bilsen M; Schroen B
Cardiovasc Res; 2018 May; 114(6):782-793. PubMed ID: 29462282
[TBL] [Abstract][Full Text] [Related]
6. Contribution of two-pore K
Chai S; Wan X; Nassal DM; Liu H; Moravec CS; Ramirez-Navarro A; Deschênes I
Am J Physiol Heart Circ Physiol; 2017 Jun; 312(6):H1144-H1153. PubMed ID: 28341634
[TBL] [Abstract][Full Text] [Related]
7. Heart Failure With Preserved Ejection Fraction Induces Beiging in Adipose Tissue.
Valero-Muñoz M; Li S; Wilson RM; Hulsmans M; Aprahamian T; Fuster JJ; Nahrendorf M; Scherer PE; Sam F
Circ Heart Fail; 2016 Jan; 9(1):e002724. PubMed ID: 26721917
[TBL] [Abstract][Full Text] [Related]
8. Optimizing the discovery and assessment of therapeutic targets in heart failure with preserved ejection fraction.
Fusco-Allison G; Li DK; Hunter B; Jackson D; Bannon PG; Lal S; O'Sullivan JF
ESC Heart Fail; 2021 Oct; 8(5):3643-3655. PubMed ID: 34342166
[TBL] [Abstract][Full Text] [Related]
9. Prevention of heart failure with preserved ejection fraction (HFpEF): reexamining microRNA-21 inhibition in the era of oligonucleotide-based therapeutics.
Ben-Nun D; Buja LM; Fuentes F
Cardiovasc Pathol; 2020; 49():107243. PubMed ID: 32629211
[TBL] [Abstract][Full Text] [Related]
10. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation.
Paulus WJ; Tschöpe C
J Am Coll Cardiol; 2013 Jul; 62(4):263-71. PubMed ID: 23684677
[TBL] [Abstract][Full Text] [Related]
11. Cell- and molecular-level mechanisms contributing to diastolic dysfunction in HFpEF.
Campbell KS; Sorrell VL
J Appl Physiol (1985); 2015 Nov; 119(10):1228-32. PubMed ID: 25911687
[TBL] [Abstract][Full Text] [Related]
12. Deranged myofilament phosphorylation and function in experimental heart failure with preserved ejection fraction.
Hamdani N; Bishu KG; von Frieling-Salewsky M; Redfield MM; Linke WA
Cardiovasc Res; 2013 Mar; 97(3):464-71. PubMed ID: 23213108
[TBL] [Abstract][Full Text] [Related]
13. Mitochondrial Dysfunction in Heart Failure With Preserved Ejection Fraction.
Kumar AA; Kelly DP; Chirinos JA
Circulation; 2019 Mar; 139(11):1435-1450. PubMed ID: 30856000
[TBL] [Abstract][Full Text] [Related]
14. Morphometric, Hemodynamic, and Multi-Omics Analyses in Heart Failure Rats with Preserved Ejection Fraction.
Zhang W; Zhang H; Yao W; Li L; Niu P; Huo Y; Tan W
Int J Mol Sci; 2020 May; 21(9):. PubMed ID: 32397533
[TBL] [Abstract][Full Text] [Related]
15. Phospholamban as a crucial determinant of the inotropic response of human pluripotent stem cell-derived ventricular cardiomyocytes and engineered 3-dimensional tissue constructs.
Chen G; Li S; Karakikes I; Ren L; Chow MZ; Chopra A; Keung W; Yan B; Chan CW; Costa KD; Kong CW; Hajjar RJ; Chen CS; Li RA
Circ Arrhythm Electrophysiol; 2015 Feb; 8(1):193-202. PubMed ID: 25504561
[TBL] [Abstract][Full Text] [Related]
16. Heart failure with preserved ejection fraction: Defining the function of ROS and NO.
Zuo L; Chuang CC; Hemmelgarn BT; Best TM
J Appl Physiol (1985); 2015 Oct; 119(8):944-51. PubMed ID: 25977452
[TBL] [Abstract][Full Text] [Related]
17. Coronary microvascular rarefaction and myocardial fibrosis in heart failure with preserved ejection fraction.
Mohammed SF; Hussain S; Mirzoyev SA; Edwards WD; Maleszewski JJ; Redfield MM
Circulation; 2015 Feb; 131(6):550-9. PubMed ID: 25552356
[TBL] [Abstract][Full Text] [Related]
18. Concise Review: Genetic and Epigenetic Regulation of Cardiac Differentiation from Human Pluripotent Stem Cells.
Fujita J; Tohyama S; Kishino Y; Okada M; Morita Y
Stem Cells; 2019 Aug; 37(8):992-1002. PubMed ID: 31021504
[TBL] [Abstract][Full Text] [Related]
19. Xbp1s-FoxO1 axis governs lipid accumulation and contractile performance in heart failure with preserved ejection fraction.
Schiattarella GG; Altamirano F; Kim SY; Tong D; Ferdous A; Piristine H; Dasgupta S; Wang X; French KM; Villalobos E; Spurgin SB; Waldman M; Jiang N; May HI; Hill TM; Luo Y; Yoo H; Zaha VG; Lavandero S; Gillette TG; Hill JA
Nat Commun; 2021 Mar; 12(1):1684. PubMed ID: 33727534
[TBL] [Abstract][Full Text] [Related]
20. MD1 deletion exaggerates cardiomyocyte autophagy induced by heart failure with preserved ejection fraction through ROS/MAPK signalling pathway.
Yang HJ; Kong B; Shuai W; Zhang JJ; Huang H
J Cell Mol Med; 2020 Aug; 24(16):9300-9312. PubMed ID: 32648659
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
